Vaxart (STU:NB11) Cyclically Adjusted PS Ratio: (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NB11 Vaxart Inc STU:NB11
50 GF Score
Price €0.60
! 3 Warning Signs
View Full Analysis

What is Vaxart Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vaxart  (STU:NB11) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Vaxart Cyclically Adjusted PS Ratio Related Terms


Vaxart Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Vaxart's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxart Cyclically Adjusted PS Ratio Chart

Vaxart Annual Data
Trend Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.96 0.00 0.15 0.42 0.31

Vaxart Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.32 0.31 0.67 0.67

STU:NB11 vs VTVT, SPRB, ENGN: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Vaxart's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxart Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vaxart's Cyclically Adjusted PS Ratio falls into.


STU:NB11
50GF Score
Vaxart Inc STU:NB11
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vaxart Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Vaxart's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Vaxart's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.098/333.9520*333.9520
=0.098

Current CPI (Jun. 2026) = 333.9520.

Vaxart Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.025 241.428 0.035
201612 1.025 241.432 1.418
201703 1.304 243.801 1.786
201706 0.025 244.955 0.034
201709 0.024 246.819 0.032
201712 0.649 246.524 0.879
201803 0.230 249.554 0.308
201806 0.073 251.989 0.097
201809 0.034 252.439 0.045
201812 0.217 251.233 0.288
201903 0.655 254.202 0.860
201906 0.005 256.143 0.007
201909 0.025 256.759 0.033
201912 0.073 256.974 0.095
202003 0.043 258.115 0.056
202006 0.006 257.797 0.008
202009 0.002 260.280 0.003
202012 0.003 260.474 0.004
202103 0.004 264.877 0.005
202106 0.001 271.696 0.001
202109 0.001 274.310 0.001
202112 0.001 278.802 0.001
202203 0.001 287.504 0.001
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.002 301.836 0.002
202306 0.000 305.109 0.000
202309 0.003 307.789 0.003
202312 0.043 306.746 0.047
202403 0.012 312.332 0.013
202406 0.032 314.175 0.034
202409 0.020 315.301 0.021
202412 0.064 315.605 0.068
202503 0.085 319.799 0.089
202506 0.151 322.561 0.156
202509 0.270 324.800 0.278
202512 0.377 324.054 0.389
202603 0.141 330.213 0.143
202606 0.098 333.952 0.098

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vaxart Business Description

Other Exchanges VXRT:USA
Address 170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically, all the business activity functions through the region of the United States.
50GF Score

Get the complete analysis for STU:NB11

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price